Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A new study shows that the Burst exercise stress test is more effective than the traditional Bruce protocol in detecting arrhythmias in CPVT patients, leading to better treatment decisions without safety concerns.
Higher midlife cardiorespiratory fitness is associated with longer healthspan, fewer chronic diseases, and extended lifespan in men and women, based on a large observational cohort study linking clinical data to Medicare claims.
Higher CKM syndrome stages correlate with adverse cardiac remodeling and increased heart failure risk in older adults, as shown in the ARIC Study.
Study finds long-term TSH suppression in postmenopausal women with thyroid cancer correlates with poorer cardiovascular health, reduced quality of life, and increased osteoporosis risk compared to controls.
A multi-center study reveals that circulatory support escalation in cardiogenic shock is associated with higher mortality and complications, but certain patient factors can predict successful outcomes.
This study highlights the role of RBM20 truncating variants in arrhythmogenic dilated cardiomyopathy, showing reduced penetrance and milder disease severity compared to pathogenic missense variants and titin truncating variants.
Shorter pre-treatment fibrin clot lysis time independently predicts higher bleeding risk in AF patients on oral anticoagulation, as evidenced by the ARISTOTLE trial.
The PURE study reveals significant global disparities in heart failure incidence and mortality, with hypertension as the leading modifiable risk factor, highlighting the need for targeted prevention and treatment strategies.
The PRAETORIAN-DFT trial demonstrates that omitting defibrillation testing in subcutaneous ICD implantation, guided by the PRAETORIAN score, is non-inferior to traditional testing for first-shock efficacy, reducing procedural risks without
A structured exercise program combining mobility therapy and resistance training in ECMO patients proved feasible and safe, with longer session times correlating with better functional performance.
A study finds bradykinin modestly contributes to blood pressure reduction with sacubitril/valsartan in chronic heart failure, highlighting ANP’s role in initial effects and bradykinin’s influence during chronic therapy.
A novel sixth-gen hs-cTnT assay with a 13 ng/L threshold safely identified twice as many low-risk MI patients at ED presentation vs fifth-gen assays, achieving >99.5% NPV in multinational validation.
New research identifies P2Y14R as a key regulator of neutrophil-platelet aggregates and NET formation in venous thrombosis, with proglumide showing promise as a therapeutic antagonist.
A randomized trial shows left bundle branch pacing significantly reduces the risk of pacing-induced cardiomyopathy and improves cardiac function compared to right ventricular pacing in high-risk patients.
A multiregistry analysis reveals that massive LVH in pediatric HCM is linked to early diagnosis, sarcomeric mutations, and heightened risks of arrhythmias, heart failure, and mortality. Nearly 25% of patients show significant LVH regression
The LEGEND trial demonstrates that a high-sensitivity troponin-based rule-out strategy significantly reduces hospital length of stay and cardiac testing while safely excluding acute myocardial infarction in emergency department patients.
A high-volume aortic center study reveals 93.6% technical success and 82.6% survival at 60 months with f/bEVAR for complex aneurysms, though reinterventions remain frequent.
A French cohort study reveals 44% of women receiving postpartum antihypertensives after HDP develop chronic hypertension within 10 years, signaling urgent gaps in long-term cardiovascular risk monitoring.
A study reveals that RV-PA coupling, measured by TAPSE/sPAP ratio, significantly predicts outcomes in HFrEF patients during GDMT up-titration, highlighting its potential as a treatment target.
PhysioSync-HF trial reveals CSP is inferior to BiVP for HFrEF patients with LBBB, challenging its role as a first-line resynchronization therapy despite cost benefits.
Open language-specific specialty feeds and department pages.